Deerfield Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Deerfield Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.5M	Hold	67,935	–	–	0.21%	60
2026 Q1	$22.5M	Hold	67,935	–	–	0.27%	58
2025 Q4	$27M	Hold	67,935	–	–	0.35%	55
2025 Q3	$31M	Sell	67,935 -77,065	-53%	-$31.4M	0.47%	49
2025 Q2	$47.3M	Hold	145,000	–	–	0.86%	28
2025 Q1	$39.2M	Sell	145,000 -191	-0.1%	-$49.1K	0.77%	29
2024 Q4	$34.2M	Buy	145,191 +191	+0.1%	+$50.2K	0.65%	37
2024 Q3	$39.9M	Buy	145,000 +25,200	+21%	+$6.56M	0.6%	36
2024 Q2	$29.1M	Buy	+119,800	New	+$18.9M	0.48%	43
2024 Q1	–	Sell	-1,574	Closed	-$301K	–	371
2023 Q4	$301K	Buy	+1,574	New	+$268K	0.01%	121
2018 Q3	–	Sell	-146,000	Closed	-$14.4M	–	104
2018 Q2	$14.4M	Hold	146,000	–	–	0.51%	70
2018 Q1	$17.4M	Buy	+146,000	New	+$18.8M	0.6%	60
2016 Q3	–	Sell	-336,000	Closed	-$18.6M	–	92
2016 Q2	$18.6M	Buy	+336,000	New	+$21.2M	0.73%	46
2014 Q3	–	Sell	-100,000	Closed	-$6.32M	–	132
2014 Q2	$6.32M	Sell	100,000 -202,000	-67%	-$12M	0.25%	83
2014 Q1	$20.3M	Buy	+302,000	New	+$23.4M	0.83%	40
2013 Q4	–	Sell	-383,158	Closed	-$24.5M	–	109
2013 Q3	$24.5M	Sell	383,158 -310,842	-45%	-$15.5M	1.14%	39
2013 Q2	$21.5M	Buy	+694,000	New	+$18.5M	1.01%	40

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deerfield Management's ALNY Position: Q2 2026 in Review

Deerfield Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 67,935 shares worth $20.5M. The position accounts for 0.21% of the portfolio, ranked #60.

Deerfield Management first reported a position in ALNY in Q2 2013 and has held it in 17 quarters since. The position peaked at $47.3M in Q2 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Deerfield Management held 67,935 shares of Alnylam Pharmaceuticals worth $20.5M as of Q2 2026.
Deerfield Management left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
Alnylam Pharmaceuticals made up 0.21% of Deerfield Management's portfolio in Q2 2026, its #60 holding.
Deerfield Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Deerfield Management's Alnylam Pharmaceuticals position peaked at $47.3M in Q2 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Deerfield Management's 13F filing for Q2 2026, filed 14 Aug 2026.